Table 3.

Prevalence of Capsule-Expressing and Acapsulate MenW and MenY Genogroups, by Isolation Time Point

Time (Participants, No.), Capsule Expression Status	MenW:cc11 2013-Strain Only		MenW:cc11 Original Strain Only		Other MenW		MenY:cc23 Only		Other MenYa
	Isolates, No. (%)	Participants, % (95% CI)	Isolates, No. (%)	Participants, % (95% CI)	Isolates, No. (%)	Participants, % (95% CI)	Isolates, No. (%)	Participants, % (95% CI)	Isolates, No. (%)	Participants, % (95% CI)
Sep (769)
On	0	0	2 (67)	0.3 (0.0–0.6)	0	0	8 (67)	1.0 (0.3–1.8)	1 (50)	0.1 (0.0–0.4)
Off	2 (100)	0.3 (0.0–0.6)	1 (33)	0.1 (0.0–0.4)	0	0	4 (33)	0.5 (0.0–0.1)	1 (50)	0.1 (0.0–0.4)
Nov (353)
On	9b (56)	2.5 (0.9–4.2)c	1 (100)	0.3 (0.0–0.8)	2 (67)	0.6 (0.0–1.3)	1 (17)	0.3 (0.0–0.8)	2 (100)	0.6 (0.0–1.3)
Off	7d (44)	2.0 (0.5–3.4)e	0	0	1 (33)	0.3 (0.0–0.8)	5 (83)	1.4 (0.2–2.6)	0	0
Mar (268)
On	17f (85)	6.3 (3.4–9.3)g	0	0	0	0	4 (57)	1.5 (0.0–2.9)	0	0
Off	3h (15)	1.1 (0.0–2.4)	0	0	4 (100)	1.5 (0.0–2.9)	3 (43)	1.1 (0.0–2.4)	2 (100)	0.7 (0.0–1.8)

Abbreviations: cc, clonal complex; CI, confidence interval.

^aSerogrouping data were unavailable for 1 MenY:cc103 isolate from March 2016.

^bFive (56%) were from participants who received MenACWY before or during registration (September 2015).

^c P < .0001, compared with the preceding time point.

^dSix (86%) were from participants who received MenACWY before or during registration (September 2015).

^e P < .01, compared with the preceding time point.

^fFourteen (82%) were from participants who received MenACWY before or during registration (September 2015).

^g P < .05, compared with the preceding time point.

^hAll 3 were from participants who received MenACWY before or during registration (September 2015).